FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068082166> ?p ?o ?g. }

• W2068082166 endingPage "1357" @default.
• W2068082166 startingPage "1349" @default.
• W2068082166 abstract "1 GYKI 52466 is a benzodiazepine derivative that has muscle relaxant and anticonvulsant properties thought to be mediated by highly selective, noncompetitive antagonism of non-NMDA receptors. However, recent electrophysiological data showed that, in addition to non-NMDA receptors, the GABAA-receptor associated benzodiazepine site is involved in the depressant effect of GYKI 52466 on spinal reflex transmission. In view of the structural similarities between the 2,3 benzodiazepine derivative GYKI 52466 and 1,4-benzodiazepines such as diazepam, the benzodiazepine site of GABAA receptor complex could also be involved in the anticonvulsant activity of GYKI 52466, which has not yet been proven. This prompted us to study the effect of the benzodiazepine receptor antagonist, flumazenil, on anticonvulsant and adverse effects of GYKI 52466 in different seizure models in mice. The non-NMDA antagonist, NBQX and diazepam were used for comparison. 2 Seizure threshold models for different types of generalized seizures were used. The threshold for maximal (tonic) electroshock seizures (MES) was significantly increased by GYKI 52466 (10–20 mg kg−1), NBQX (80–120 mg kg−1) and diazepam (5 mg kg−1) shortly after i.p. drug administration. The same dose-range of the non-NMDA antagonists also significantly increased the threshold for myoclonic and clonic seizures induced by i.v. infusion of pentylenetetrazol (PTZ), although the magnitude of threshold increases obtained with the respective drugs, differed, at least in part, from that seen in the MES experiments. GYKI 52466 was clearly less potent in increasing PTZ thresholds for myoclonic and clonic seizures than on the MES threshold, while NBQX exerted about the same potency in both models. In contrast to the non-NMDA antagonists, diazepam was capable of increasing the myoclonic and clonic PTZ seizure threshold at much lower doses than the MES threshold. The PTZ threshold for tonic seizures was markedly increased by GYKI 52466, while NBQX and diazepam were clearly less potent in this respect. 3 With respect to adverse effects, GYKI 52466 and NBQX induced significant seizure threshold increases in the different seizure models only at doses which caused sedation and ataxia, while diazepam increased the myoclonic and clonic PTZ seizure threshold at doses below those inducing motor impairment. 4 Flumazenil (5–20 mg kg−1) antagonized the anticonvulsant and adverse effects of diazepam but not GYKI 52466. Instead, the anticonvulsant effect of GYKI 52466 was potentiated by flumazenil in some experiments. The anticonvulsant activity of NBQX was slightly reduced by flumazenil in the MES model but not in the PTZ test. 5 The data indicate that the GABAA receptor-associated benzodiazepine site is not critically involved in anticonvulsant or adverse effects of GYKI 52466. However, both GYKI 52466 and NBQX were unable to increase seizure thresholds at doses below those inducing sedation and motor impairment, thus demonstrating that non-NMDA antagonists lack a selective anticonvulsant action in standard models of generalized seizures." @default.
• W2068082166 created "2016-06-24" @default.
• W2068082166 creator A5010235451 @default.
• W2068082166 creator A5055852211 @default.
• W2068082166 date "1994-12-01" @default.
• W2068082166 modified "2023-09-29" @default.
• W2068082166 title "Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil" @default.
• W2068082166 cites W1534847569 @default.
• W2068082166 cites W1591177630 @default.
• W2068082166 cites W1836952133 @default.
• W2068082166 cites W1971265518 @default.
• W2068082166 cites W1978342290 @default.
• W2068082166 cites W1978346590 @default.
• W2068082166 cites W1978376339 @default.
• W2068082166 cites W1981649830 @default.
• W2068082166 cites W1982215096 @default.
• W2068082166 cites W1983404085 @default.
• W2068082166 cites W1992064771 @default.
• W2068082166 cites W1994084016 @default.
• W2068082166 cites W1996340934 @default.
• W2068082166 cites W1996590069 @default.
• W2068082166 cites W2020835806 @default.
• W2068082166 cites W2022786081 @default.
• W2068082166 cites W2029462182 @default.
• W2068082166 cites W2032216760 @default.
• W2068082166 cites W2037997999 @default.
• W2068082166 cites W2038704879 @default.
• W2068082166 cites W2041298933 @default.
• W2068082166 cites W2046649305 @default.
• W2068082166 cites W2047744286 @default.
• W2068082166 cites W2051875864 @default.
• W2068082166 cites W2052249757 @default.
• W2068082166 cites W2054140492 @default.
• W2068082166 cites W2067686370 @default.
• W2068082166 cites W2069427780 @default.
• W2068082166 cites W2071529758 @default.
• W2068082166 cites W2072465507 @default.
• W2068082166 cites W2074297151 @default.
• W2068082166 cites W2080803760 @default.
• W2068082166 cites W2091076275 @default.
• W2068082166 cites W2091837097 @default.
• W2068082166 cites W2093462886 @default.
• W2068082166 cites W2122597724 @default.
• W2068082166 cites W2167825748 @default.
• W2068082166 cites W2169883166 @default.
• W2068082166 cites W2245432458 @default.
• W2068082166 cites W2248970389 @default.
• W2068082166 cites W2336146742 @default.
• W2068082166 cites W2409284343 @default.
• W2068082166 cites W34455977 @default.
• W2068082166 doi "https://doi.org/10.1111/j.1476-5381.1994.tb17146.x" @default.
• W2068082166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1510537" @default.
• W2068082166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7889291" @default.
• W2068082166 hasPublicationYear "1994" @default.
• W2068082166 type Work @default.
• W2068082166 sameAs 2068082166 @default.
• W2068082166 citedByCount "64" @default.
• W2068082166 countsByYear W20680821662012 @default.
• W2068082166 countsByYear W20680821662015 @default.
• W2068082166 countsByYear W20680821662016 @default.
• W2068082166 countsByYear W20680821662017 @default.
• W2068082166 countsByYear W20680821662018 @default.
• W2068082166 countsByYear W20680821662019 @default.
• W2068082166 countsByYear W20680821662021 @default.
• W2068082166 countsByYear W20680821662023 @default.
• W2068082166 crossrefType "journal-article" @default.
• W2068082166 hasAuthorship W2068082166A5010235451 @default.
• W2068082166 hasAuthorship W2068082166A5055852211 @default.
• W2068082166 hasBestOaLocation W20680821662 @default.
• W2068082166 hasConcept C15744967 @default.
• W2068082166 hasConcept C160268369 @default.
• W2068082166 hasConcept C168258287 @default.
• W2068082166 hasConcept C169760540 @default.
• W2068082166 hasConcept C170493617 @default.
• W2068082166 hasConcept C185592680 @default.
• W2068082166 hasConcept C2775858608 @default.
• W2068082166 hasConcept C2776175493 @default.
• W2068082166 hasConcept C2776819090 @default.
• W2068082166 hasConcept C2776885963 @default.
• W2068082166 hasConcept C2777836312 @default.
• W2068082166 hasConcept C2778173252 @default.
• W2068082166 hasConcept C2778186239 @default.
• W2068082166 hasConcept C2778409475 @default.
• W2068082166 hasConcept C2778460930 @default.
• W2068082166 hasConcept C2780076171 @default.
• W2068082166 hasConcept C42219234 @default.
• W2068082166 hasConcept C55493867 @default.
• W2068082166 hasConcept C67018056 @default.
• W2068082166 hasConcept C71924100 @default.
• W2068082166 hasConcept C98274493 @default.
• W2068082166 hasConceptScore W2068082166C15744967 @default.
• W2068082166 hasConceptScore W2068082166C160268369 @default.
• W2068082166 hasConceptScore W2068082166C168258287 @default.
• W2068082166 hasConceptScore W2068082166C169760540 @default.
• W2068082166 hasConceptScore W2068082166C170493617 @default.
• W2068082166 hasConceptScore W2068082166C185592680 @default.
• W2068082166 hasConceptScore W2068082166C2775858608 @default.
• W2068082166 hasConceptScore W2068082166C2776175493 @default.

• next